开元官网登录入口

Chengdu, Sichuan, China - On October 18, 2022, MicroPort Scientific Corporation (hereinafter referred to as “MicroPort^®”) and the West China Hospital of Sichuan University (hereinafter referred to as “West China Hospital”) signed a strategic cooperation agreement. Based on the advantages of their respective medical resources and technology platforms, the two parties will establish an all-round, broad-coverage and diversified cooperation system integrating “industry, universities, research institutes, and medical establishments”, actively promote the in-depth practice and innovation of medical-engineering cooperation, and strive to become a regional leader in the realm of medicine, so as to contribute to the “Healthy China” initiative. On the same day, the opening ceremony of the “West China Hospital - MicroPort^® MedBot^® Robotic Surgery Training Center” co-built by MicroPort^® MedBot^®, a subgroup of MicroPort^®, and the West China Hospital, was successfully held alongside the 5G in-car test drive event. The establishment of the Center will facilitate the 5G remote surgery technology to reach more primary-level hospitals for the benefit of more patients, thereby accelerating the process of intelligence medicine in southwest China.

The signing and inauguration ceremony was attended by Weimin Li, President of the West China Hospital, Kunjie Wang, Hong Wu and Lei Chen, Vice Presidents of the hospital, Xin Zhao, Director of the President’s Office of the hospital, Dajiang Li, Director of the Medical Department of the hospital, Zheng Wang, Director of the Science and Technology Department, Jian Pu, Director of the Discipline Construction Department, Xiaodong Wu, Director of the Equipment and Materials Department, Dan Liu, Director of the Respiratory and Intensive Care Medicine Department, Mao Chen, Director of Cardiology, Qiang Dong, Director of Urology, Dan Pu, Director of the Clinical Skills Center, Wuran Wei, expert from the Urology Department, Zhaohua Chang, Chairman and CEO of MicroPort^®, Lihong Zhang, Senior Vice President of Intellectual Property Rights of the group, Chao He, President of MicroPort^® MedBot^®, Yu Liu, Executive Vice President and Chief Commercial Officer, Haitao Zhang, Senior Director of Clinical Training, and Langke Wu, Sales Director.

At the signing ceremony, both parties reached a consensus that based on their advantages in medical resources and technology platforms, they will focus on the in-depth cooperation in proof of concept on medical innovation, joint R&D of medical devices, clinical validation and research, clinical training bases for innovative medical devices, medical-engineering training and academic exchange, and scientific research project declaration, in an effort to explore a new system and new mode of collaborative innovation between industry, universities, research institutes, and medical establishments, thus contributing their own wisdom and strength to the “Healthy China” initiative.

Weimin Li, President of the West China Hospital, pointed out in his speech that MicroPort^® has cracked a series of bottlenecks in minimally invasive surgeries in the past, providing first-class products for patients at home and abroad. The West China Hospital has abundant clinical resources, a strong basic research platform and a broad base of medical alliance cooperation. Therefore, the strategic cooperation between the two sides is of great significance. In the future, both parties will seek more extensive and in-depth exchanges and cooperation based on clinical problems, the development goals proposed in the “Five Medical Linkage” that integrates medical treatment, medical insurance, medicine, medical care, and medical reform, and the resources in technology, clinical and scientific innovation, so as to implement the strategy of revitalizing the country through science and education and the “Healthy China” initiative with concrete actions, thereby jointly facilitating the advancement of minimally invasive medicine.

Dr. Zhaohua Chang, Chairman and CEO of MicroPort^®, said, “The current strategic cooperation reached embodies our joint exploration with the West China Hospital, and all business sections of MicroPort^® are highly excited. MicroPort^® currently has a 100 percent conversion rate of scientific and technological achievements and has over 110 projects in medical-engineering cooperation. Furthermore, we have abundant talent and capital resources, and our sound basic platform enables us to integrate resources and provide comprehensive cooperation involving various departments for the West China Hospital. We hope that this deepened partnership will become a new paradigm of medical-engineering cooperation and thus empower the development of medical industry.

Dr. Chao He, President of MicroPort^® MedBot^®, said, “The cooperation with the West China Hospital aims to explore and open up a mature development path of medical-engineering integration with Chinese characteristics. MicroPort^® provides an integrated solution for the hospital through an innovative closed loop that begins and ends with surgeons. In terms of building a remote robotic surgery center, MicroPort^® MedBot^® looks forward to digging deeper into two key directions with the West China Hospital: first, to establish a robotic remote surgery system for the West China Hospital that connects different hospital areas via 5G; second, to build a robotic remote surgery alliance in the southwest region, with the West China Hospital as the center. Depending on 5G remote technology, MicroPort^® MedBot^® will promote the integration of regional medical development, address the inconvenience of patients' off-site medical treatment, so that they can have access to remote surgery treatment by top medical experts “without leaving their own county or city”.

After the signing ceremony, Dr. Weimin Li, President of the West China Hospital, and Dr. Zhaohua Chang, Chairman and CEO of MicroPort^®, inaugurated the “West China Hospital - MicroPort^® MedBot^® Robotics Surgery Training Center”.

At the inauguration ceremony, President Weimin Li also unveiled a small plaque inside the simulated abdominal prop remotely through the surgical console of the Toumai^® Laparoscopic Surgical Robot. He said afterwards that the remote operating system of the Toumai^® Laparoscopic Surgical Robot is highly flexible and precise with excellent experience of human-robotic collaboration. The attendees witnessed this innovative ceremony and participated in the test drive of the vehicle-mounted robot one after another.

After the test drive, experts and leaders from various departments of the West China Hospital highly recognized the stable performance and high-definition vision of Toumai^® Laparoscopic Surgical Robot, and expressed their hope that the advantages of robotics in performing delicate and minimally invasive surgeries can be applied and implemented in the West China Hospital as soon as possible.

The launch of the “West China Hospital - MicroPort^® MedBot^® Robotics Surgery Training Center” will further facilitate the accessibility of robotics into southwest China and improve the diagnosis and treatment capability of related hospitals through the training of medical personnel. In the future, through 5G telesurgery, the joint construction of a remote robotic surgery alliance, with the West China Hospital as the center, will greatly improve the ability of hospitals in remote areas to perform complex surgeries, enable medical resources to reach more areas, and resolve the uneven distribution of high-end mature medical resources due to the gaps in regional development. This is an effective innovation in response to the reform of the medical system of the National Health Commission, which also perfectly embodies the original mission of MicroPort^® MedBot^® to “Make Surgery Easier, Safer and Less Invasive”.

The West China Hospital serves as a national center for the treatment of complicated and severe illnesses in western China, whose medical capacity ranks among the top domestically. There are 32 national clinical key specialties of the National Health Commission, whose number ranks the top among all the hospitals in China. Its overall ranking has been No.2 in the country for 11 years in the chart of Chinese hospitals issued by Fudan University. 38 specialties of the West China Hospital have participated in the comprehensive ranking of specialties, with 12 departments among the top three on the list, including one that ranks No.1 (anesthesiology), three that rank second (radiology, urology, and ultrasound medicine), and eight that rank third (pathology, geriatrics, general surgery, neurosurgery, respiratory medicine, rehabilitation medicine, laboratory medicine, and intensive care medicine). In addition, the hospital has 20 specialties that rank top five, 3 new ones compared to last year, with those ranking 4th-5th including emergency medicine, thoracic surgery, psychiatry, nuclear medicine, neurology, rheumatology, orthopedics, and infectious diseases. There are 30 specialties in the hospital that are among top ten, with those ranking 6^th-10^th including gastroenterology, endocrinology, oncology cardiac surgery, cardiovascular disease, general medicine, hematology, dermatology, allergic reactions, and tuberculosis.

Founded in 1998 in Zhangjiang Science City, Shanghai, China, MicroPort^® is an innovative high-end medical device group focusing on 12 business clusters, including cardiovascular and structural heart disease, electrophysiology and cardiac rhythm management systems, bone and soft tissue repair technology, aortic and peripheral vascular disease, cerebrovascular and neuromodulation science, surgical emergencies and robotics, endocrine management and assisted reproduction, urogynecology, digestive and respiratory diseases, ear, nose, mouth, eye and body cosmetic medicine, in vitro diagnosis and in vivo/vitro imaging, solid tumor treatment technology, insomnia, depression, and rehabilitation medicine.

MicroPort^® has established major production (R&D) bases in Shanghai, Suzhou, Jiaxing and Shenzhen in China, Memphis in the United States, Paris suburbs in France, Milan suburbs in Italy and the Dominican Republic, forming a global R&D, production, marketing and service network. MicroPort^® is committed to providing universally accessible solutions that can reshape and prolong lives for the benefit of more people.

Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort^® MedBot^®, stock code: 02252.HK) is a sub-group of MicroPort^® Scientific Corporation (MicroPort^®, stock code: 00853.HK). It initiated the development of Toumai^® Laparoscopic Surgical Robot in 2014 as an internal incubation project of MicroPort^®, established the company in China in 2015 to start its corporate operation, and kickstarted the development of Honghu Orthopedic Surgical Robot. On November 2, 2021, MicroPort^® MedBot^® was successfully listed on the Main Board of HKEX, assuming the mission to reshape and prolong life through a robotic intelligent surgical total solution. This milestone event marks its new journey of medical technology innovation to shape the era of ultra-intelligent surgeries and its endeavor to fulfill the founding aspiration to “Make Surgery Easier, Safer and Less Invasive”.